Edition:
United Kingdom

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

6.45USD
17 Aug 2018
Change (% chg)

$0.05 (+0.78%)
Prev Close
$6.40
Open
$6.40
Day's High
$6.45
Day's Low
$6.40
Volume
867
Avg. Vol
7,484
52-wk High
$7.35
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

FDA Clears Development Pathway For Nexobrid For Sulfur Mustard Injuries
Tuesday, 29 May 2018 

May 29 (Reuters) - Mediwound Ltd ::FDA CLEARS DEVELOPMENT PATHWAY FOR NEXOBRID® FOR SULFUR MUSTARD INJURIES.MEDIWOUND LTD - FDA ALSO AGREED THAT SINGLE ANIMAL SPECIES TRIALS WOULD SUFFICE, SUBJECT TO ADEQUATE SAFETY AND EFFICIENCY DATA FROM PLANNED STUDIES.MEDIWOUND - FDA AGREED TO RELY ON EXISTING CMC INFORMATION ALREADY AVAILABLE FOR NEXOBRID BY WAY OF CROSS-REFERENCE TO EXISTING NEXOBRID IND FOR BURNS.  Full Article

MediWound Q3 loss per share $0.49
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - MediWound Ltd -:MediWound reports third quarter 2017 financial results.Q3 loss per share $0.49.Q3 revenue $740,000 versus I/B/E/S view $790,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.MediWound - ‍expected cash use to support operating activities in 2017 will remain toward lower end of co's guidance range for 2017 of $15 million -$17 million​.MediWound Ltd - ‍company may bear an additional $1.5 million expense to purchase shares of PolyHeal pursuant to district court ruling in Q4 of 2017​.  Full Article

Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Mediwound Ltd :Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal.‍Continues to evaluate ruling and its legal and accounting implications and company's options, including a potential appeal​.Court ordered that co is obligated to purchases shares of 3 shareholders of PolyHeal pursuant to claim made by such PolyHeal shareholders​.  Full Article

MediWound appoints Mr. Stephen T. Wills as chairman
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Mediwound Ltd :MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors.Mediwound Ltd - ‍ appointment of Stephen T. Wills as chairman upon resignation of Aharon Yaari from Board​.Mediwound Ltd - ‍ Wills currently serves as Chief Financial Officer and Chief Operating Officer of Palatin Technologies​.  Full Article

MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid
Monday, 16 Oct 2017 

Oct 16 (Reuters) - MediWound Ltd :MediWound Ltd - ‍ announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns​.  Full Article

Mediwound reports final positive results of phase 2 clinical trial of Escharex
Tuesday, 31 Jan 2017 

Mediwound Ltd : Mediwound reports final positive results of phase 2 clinical trial of escharex for the debridement of chronic and hard-to-heal wounds . Based on final clinical study report, phase 2 clinical trial of escharex met its statistically-powered primary endpoint 2 .Mediwound ltd- expect to complete second cohort of phase 2 study and to report top-line data in mid-2017.  Full Article

BRIEF-MediWound Reports Q1 Loss Per Share Of $0.17

* Q1 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S